Measure 109 would make Oregon the first state in the nation allowed to manufacture, deliver and administer psilocybin products and psilocybin-assisted therapy at supervised and licensed facilities.
The measure, if voters in November pass it, also would impose a two-year development period for the Oregon Health Authority to establish parameters for the new therapy.
Some of Oregon’s medical and psychiatric leaders, including the Oregon Psychiatric Physicians Association, argue the measure isn’t what it seems, and the effects of the therapy have not been adequately studied.
Read the full story here.
Natalie Pate 